PMID: 37425048 J Clin Invest2025 Oct 15;135(20):e195214
SIN EFECTOS SECUNDARIOS Elaborado a base de CLA, Carnitina y Especies vegetales (contiene cafena), carece de efectos secundarios, efecto rebote en cuando se deja de tomar ni contraindicaciones con otros complementos alimenticios o medicamentos.
Neurologic and Metabolic Disorders It may also serve as adjunctive therapy in: Chronic fatigue syndromes Diabetic neuropathy Insulin resistance or metabolic syndrome Age-related mitochondrial decline Dosing and Administration Route : IM injection (preferred for general use), IV infusion (under clinical guidance) Typical IM dose : 5001,000 mg, 13 times per week IV use : 12 grams diluted in compatible carrier solution (e.g., saline), infused over 3060 minutes Dosing frequency is patient-specific and may be adjusted based on clinical response , exercise load , or lab values Safety and Considerations L-Carnitine is generally well tolerated when administered properly
And it can certainly be indicated for those who have a deficiency in their own production of carnitine and are vegetarians
Physiol Revs 1983;63:1420-79 2 -Scholte HR ea in Gitzelmann R ea, eds, Carnitin in der Medizin, Schattauer, Stuttgart, 1987:21-59 3 -Scholte HR ea in Seim H ea, eds Carnitine-Pathochemical Basics and Clinical Applications, Ponte Press, Bochum,1996:11-31 4 -Bremer J in DeSimone C ea eds
10.1016/j.metabol.2010.03.010 56